PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Prucalopride - Constipation

PAD Profile : Prucalopride - Constipation

Keywords :
NICE
Brand Names Include :
Resolor

Traffic Light Status

Status 1 of 1.

Status :
Green
Important
Formulations :
  • Tablets
Important Information :
Only after a trial of at least 2 other classes of laxative at the highest recommended, tolerated doses. Consider stopping after 4 weeks if not effective.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.

Management | Constipation | CKS | NICE

The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.

Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.

02 October 2019
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Treatment with prucalopride (October 2019 review)

1. Patient should have been treated with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, and these treatments have failed to provide adequate relief and invasive treatment for constipation is being considered.

2. If treatment is not effective after 4 weeks then consider stopping treatment.

Associated BNF Codes

01. Gastro-Intestinal System
01.06.07. Other drugs used in constipation
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More